Novartis (NOVN) vs Eli Lilly (LLY)
Novartis (NOVN) and Eli Lilly (LLY) side by side: both in Healthcare, listed on SIX Swiss Exchange and New York Stock Exchange. Eli Lilly is the larger of the two by approximate market capitalization (about 3.8×).
| Field | Novartis | Eli Lilly |
|---|---|---|
| Legal name | Novartis AG | Eli Lilly and Company |
| Ticker | NOVN | LLY |
| Exchange | SIX Swiss Exchange XSWX | New York Stock Exchange XNYS |
| Jurisdiction | Switzerland | United States |
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Market cap ≈ | $292.4bn | $1.1tn |
| Founded | 1996 | 1876 |
| Reporting currency | CHF | USD |
| LEI | 5493007HIVTX6SY6XD66 | FRDRIPF3EKNDJ2CQJL29 |
| ISIN | CH0012005267 | US5324571083 |
| FIGI | BBG001SD31N7 | BBG001S5STL8 |
| Index membership | — | S&P 500 |
| Held by (covered funds) | — | 1 |
Novartis
Basel-based pharmaceutical company created by the 1996 merger of Ciba-Geigy and Sandoz, now a pure-play innovative-medicines business after spinning off Alcon and Sandoz. Key franchises include cardiovascular, oncology and immunology drugs.
Eli Lilly
Pharmaceutical maker; GLP-1 metabolic drugs (Mounjaro, Zepbound), oncology and neuroscience.
Market caps are computed from each issuer's own filed share count times the close on 2026-08-28, not copied from a vendor; LEI from GLEIF (CC0), ISIN read from each issuer's own primary listing document with its ISO 6166 check digit validated, FIGI from OpenFIGI, MIC from the ISO 10383 registry — full provenance on Sources. Not real-time, not investment advice. Both sides as data: /api/v1/companies/novartis · /api/v1/companies/eli-lilly